|
Larimar Therapeutics Inc (NASDAQ: LRMR) |
|
Larimar Therapeutics Inc
LRMR's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Larimar Therapeutics Inc 's sales fell
in IV. Quarter 2024 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
growth of revenues by 11.85 %
Larimar Therapeutics Inc net loss increased from $-13 millions, to $-29 millions in IV. Quarter 2024,
• More on LRMR's Growth
|
|
Larimar Therapeutics Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 24.8 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.27.
• More on LRMR's Valuation
|
|
|
|
|
Larimar Therapeutics Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 24.8 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.27.
Larimar Therapeutics Inc Price to Book Ratio is at 0.83 lower than Industry Avg. of 79.76. and higher than S&P 500 Avg. of 0.01
• More on LRMR's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com